NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Tuesday, July, 30th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.02. The medical research company earned $101.71 million during the quarter, compared to analysts' expectations of $97.32 million. NeoGenomics had a return on equity of 4.97% and a net margin of 0.57%. The company's revenue for the quarter was up 50.1% compared to the same quarter last year. During the same period last year, the business posted $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for NeoGenomics.

NeoGenomics will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NeoGenomics updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of $0.23-0.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $388-402 million, compared to the consensus revenue estimate of $393.32 million.

7 brokers have issued 1-year price targets for NeoGenomics' shares. Their predictions range from $15.00 to $30.00. On average, they expect NeoGenomics' share price to reach $24.57 in the next year. This suggests a possible upside of 24.7% from the stock's current price. View Analyst Price Targets for NeoGenomics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News stories about NEO stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NeoGenomics earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in September. As of September 30th, there was short interest totalling 5,500,000 shares, an increase of 13.2% from the August 30th total of 4,860,000 shares. Based on an average daily volume of 863,900 shares, the days-to-cover ratio is currently 6.4 days. Currently, 5.6% of the company's stock are short sold. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Avantor (AVTR), IPSEN S A/S (IPSEY), Masimo (MASI), Icon (ICLR), Novocure (NVCR), BIO-TECHNE (TECH), ABIOMED (ABMD), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Perrigo (PRGO), Recordati (RCDTF), Catalent (CTLT), Molina Healthcare (MOH), SAGE Therapeutics (SAGE) and NMC HEALTH PLC/ADR (NMHLY).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), Amarin (AMRN) and AT&T (T).

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%) and Juncture Wealth Strategies LLC (0.01%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Juncture Wealth Strategies LLC. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $19.70.

NeoGenomics has a market capitalization of $2.05 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]